ABUS News and Press, Arbutus Biopharma Corporation From 08/30/23

2023-08-30 16:04:07 ET Summary Moderna and Pfizer/BioNTech earned more than $110 billion from their COVID vaccines, with net profit margins of more than 50%. Alnylam, Arbutus and Genevant are suing Moderna, Pfizer, and BioNTech, alleging they infringed on patents for lipid nanopar...

2023-08-03 15:18:02 ET Arbutus Biopharma Corporation (ABUS) Q2 2023 Earnings Conference Call August 03, 2023 08:45 AM ET Company Participants Lisa Caperelli - VP of IR Bill Collier - President, CEO and Director David Hastings - CFO Karen Sims - VP of Clinical...

2023-08-03 07:41:06 ET Arbutus Biopharma press release ( NASDAQ: ABUS ): Q2 GAAP EPS of -$0.10 beats by $0.01 . Revenue of $4.65M (-67.3% Y/Y) misses by $1.55M . The decrease of $9.5 million for the 2023 period was due primarily to lower revenue recognition fro...

Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in combination with pegylated interferon alfa-2a, in a Phase 2a clinical trial, was generally well tol...

2023-08-02 14:27:01 ET Arbutus Biopharma ( NASDAQ: ABUS ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.11 and the consensus Revenue Estimate is $6.2M (-56.5% Y/Y). Over the last 3 months, EP...

WARMINSTER, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its seco...

WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral...

2023-07-11 03:46:29 ET Arbutus Biopharma ( NASDAQ: ABUS ) has promoted Karen Sims as Chief Medical Officer and named Christopher Naftzger as General Counsel and Chief Compliance Officer, effective immediately.. Naftzger succeeds Elizabeth Howard&#x...

Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopha...

Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveragi...